Our findings therefore provide a novel insight into the role of hypoxia in programming DCs primed Th2 responses via a KIF2A/MT1-MMP/CD44 pathway and implicate that hypoxia might be a promising therapeutic approach in allergic diseases. This evidence concerns the gene MMP14 and allergic disease.